Tuesday, March 3, 2026

The Daily

A Curated Briefing

🌤️ Vienna Partly cloudy, morning fog clearing • Some sun, afternoon clouds 4–14°C Moderate SE wind

Biotech & Pharma

FDA Setback

UniQure Faces Sham Brain Surgery Demand — FDA's Controversial Call on Huntington's Gene Therapy

The FDA "strongly recommended" UniQure conduct a new randomized, double-blind trial comparing AMT-130 to sham brain surgery — a worst-case scenario for the company. The gene therapy requires drilling into the skull for intracranial delivery, meaning the control group would undergo invasive surgery without receiving treatment. UniQure is weighing options but called the approach "inconsistent with ethical standards." Analysts see this as a major setback for the Huntington's pipeline.

BioPharma Dive, STAT News, Reuters, Bloomberg • March 2, 2026
Kidney Cancer Breakthrough

Merck's Welireg + Keytruda Combo Cuts RCC Recurrence Risk 28%

First positive Phase 3 trial for HIF-2α inhibitor in adjuvant setting. LITESPARK-022 data at ASCO GU showed Welireg (belzutifan) + Keytruda reduced disease recurrence or death vs. Keytruda alone in earlier-stage renal cell carcinoma. Dual data drop also included advanced RCC combination results.

Merck, Fierce Pharma, AllSci
Vaccine Policy

RFK Jr. Picks New ACIP Members Again — Vaccine Advisory Committee Overhaul Continues

HHS Secretary Robert F. Kennedy Jr. announced a second wave of new members for the CDC's vaccine advisory committee, extending a controversial restructuring. Critics worry the changes signal a shift in U.S. immunization policy. PharmaVoice highlighted Stanley Plotkin's concerns: the "godfather of vaccines" says he regrets living long enough to see his field's achievements slip away.

STAT News, Endpoints Pharma, PharmaVoice

Science / Immuno-Oncology

Study • ZUMA-2 Retrospective
Blood Advances

Ibrutinib Exposure Boosts CAR-T Efficacy in Mantle Cell Lymphoma — BTKi "Priming" Effect Revealed

A retrospective analysis of the ZUMA-2 trial reveals that patients previously exposed to ibrutinib (first-generation BTKi) had significantly better outcomes with brexucabtagene autoleucel than those exposed to acalabrutinib (second-generation). Ibrutinib-treated patients showed greater CAR T-cell expansion, more effector memory differentiation at day 7, and increased T helper 17 frequencies in the product. The findings suggest BTK inhibitor class may "prime" the tumor microenvironment for CAR-T success — a potentially critical variable for future trials and sequencing decisions.

Darnell EP et al., Blood Adv. 2026 Feb 24 • PMID 41733967
Study • Resistance Mechanisms
Blood

Glofitamab Resistance Linked to Exhausted CD8+ T-Cells and Elevated Tfh

Patient-derived lymphoma spheroids (PDLS) from 39 R/R B-NHL patients reveal glofitamab low responders show enrichment of exhausted CD8+ T-cells (TIGIT, LAG3, PD1) and elevated functional CD4+ T-follicular helper cells. Tfh proximity to malignant B-cells promotes survival via IL21 and CXCL13. Anti-TIGIT co-treatment enhanced efficacy in low responders.

Marcoux P et al., Blood 2026 • PMID 41746860
Study • mRNA Delivery Platform
Nature

Pancreatic-Targeted LNP Boosts CAR-T Combo in Pancreatic Cancer

New lipid nanoparticle (AH-LNP) achieves pancreatic-selective mRNA delivery via organ capsule filtration. Enables precise genome editing (Cas9/sgRNA) for autoimmune pancreatic diseases and delivers therapeutic cytokines for cancer vaccines + CAR-T combinations in multiple pancreatic cancer models. Safety verified in non-human primates.

Lei J et al., Nature 2026 Feb 25 • PMID 41741655
Study • HIV CAR-T Setback
Blood

CD4 CAR-T for HIV Fails to Control Viremia in Multiple NHP Models

Despite promising in vitro proliferation and cytotoxicity, antigen-boosted CD4 CAR-T cells failed to expand, persist, or control viremia in multiple non-human primate models (SIV, SHIV). Strategies included CRISPR editing, checkpoint gene knockouts, and pooled competitive infusions. Low antigen levels in ART-suppressed settings remain a major barrier.

Maynard L et al., Blood 2026 Feb 24 • PMID 41734346
Study • Relmacabtagene Phase 2
Blood Advances

Relmacabtagene (CD19 CAR-T) Shows 71% ORR in R/R MCL — Chinese Phase 2 Data

Relma-cel, approved in China for R/R large B-cell lymphoma and follicular lymphoma, demonstrates 71.19% ORR (59.32% CR rate) in heavily pretreated mantle cell lymphoma. Median DOR 18.1 months, PFS 15.5 months, OS 19.5 months. Grade 3+ CRS and neurotoxicity each 6.8%, all resolved fully. No fatal events.

Xie Y et al., Blood Adv. 2026 Feb 24 • PMID 41733966

AI & Technology

Breaking

OpenAI Steps Into Pentagon Void After Anthropic Walks — Claude Hits 500K Downloads Saturday

Hours after Anthropic refused Pentagon demands for classified network deployment, OpenAI announced a deal with ethical safeguards on Sunday. The agreement includes guardrails against mass surveillance and fully autonomous weaponry — red lines Anthropic held firm on. Meanwhile, Claude's mobile app saw over 500,000 downloads on Saturday, its biggest day on record, as users rallied behind Anthropic's stance. Over 50 OpenAI and 175 Google employees signed an open letter urging their companies to reject similar Pentagon demands.

The Rundown AI, Superhuman, Forward Future, Exponential View • March 2, 2026
AI Ethics

Google and OpenAI Employees Rally Behind Anthropic's Pentagon Red Lines

50 OpenAI + 175 Google employees signed an open letter urging leadership to reject Pentagon demands for AI systems without safeguards. The letter highlights Anthropic's refusal to deploy Claude on classified networks as a model for industry ethics. Max Tegmark argues AI companies resisted regulation for years, now shocked the government wants control.

Exponential View, TechCrunch, The Guardian
Industry

Elon Musk's Secret Web of Companies in Texas

New York Times investigation reveals Musk has quietly built an interconnected network of companies in Texas, leveraging cross-company synergies and state incentives. The NYT On Tech newsletter explores how this infrastructure positions him for AI, energy, and manufacturing dominance in the region.

NYT On Tech • March 2, 2026

NBA News

Sunday's Scores

Celtics Demolish Bucks 108-81 — Milwaukee's Struggles Deepen

Boston delivered a 27-point road beatdown in Milwaukee, handing the Bucks their 19th road loss of the season. The Celtics (41-20) shot lights out while the Bucks (26-34) continued their slide despite keeping Giannis at the trade deadline. Milwaukee's home record now sits at a mediocre 14-15, raising questions about their postseason viability.

ESPN • March 2, 2026
Sunday Recap

Rockets Extend Road Success 123-118 Over Wizards

Houston (38-22) continues their strong away form with a victory in Washington. The Rockets are now 18-15 on the road, a key factor in their playoff push. Wizards (16-44) remain in the cellar despite a competitive showing.

ESPN

Travel

Destination

Why 2026 Is the Year to Visit Venice — New Hotels, Biennale Arte, and Post-Carnival Calm

Condé Nast Traveler makes the case: Venice in March 2026 hits a sweet spot. Carnival crowds have just left, Easter tourists haven't arrived yet, and the city debuts a clutch of new hotels alongside a hyperlocal food scene. The Biennale Arte returns May 9–November 22, honoring late curator Koyo Kouoh with the theme "In Minor Keys." Day-tripper fees fund infrastructure improvements, making this the year to experience Venice before it changes again.

Condé Nast Traveler • January 2026
Italy Travel Guide

Italy in March: Where It's Actually Worth Going (and What to Skip)

Anthony, who's lived in Umbria since 2022, offers unvarnished advice for early spring travel. March can be magic if you time it right — or two weeks dodging rain with a broken street-vendor umbrella. His guide highlights regions that work in shoulder season and warns against tourist traps before they're ready.

Anthony in Italy • Feb 2026
Italy Segreta

26 Places to Go in Italy in 2026 — Beyond the Basic Venice-Florence-Rome Circuit

Italy Segreta makes a New Year's resolution: retire the over-touristed Venice, Florence, Rome, Amalfi Coast circuit. While those cities are extraordinary, relying solely on them ignores the staggering, beautiful vastness of Italy. The guide spotlights 26 destinations that deserve attention in 2026.

Italy Segreta • Jan 2026

Wien für Kinder

März-Highlights

Frühlingsvaganza Kunstmarkt in der Semmelweisklinik — 21.–22. März

Am Wochenende vom 21. und 22. März findet zum zweiten Mal der Frühlingsvaganza Kunstmarkt in der Semmelweisklinik statt. Familien erwarten Kunst und Kunsthandwerk, künstlerische Interventionen und kulinarische Köstlichkeiten. Ein kreatives Event zum Frühlingsstart, das Kindern und Erwachsenen gleichermaßen Spaß macht.

1000things Magazine • März 2026
WIENXTRA

Aktivitäten für Kinder in Wien — Gratis & Günstig

WIENXTRA bietet laufend Programm fürs Wochenende, Kinderkurse und Tipps für den Familienalltag. Die Spielebox (Albertgasse 37, 1080) öffnet Mo/Mi/Fr 13:00–18:30, Sa (Okt–März) 10:00–14:00. Die Stadtbox (Barbara-Prammer-Allee 11, 1220) ist der ideale Ort für Kinder, um die Stadt mitzugestalten.

WIENXTRA

Wien – Kultur & Essen

Neueröffnung März

Partenope — Authentische Fischküche mitten in Mariahilf

Ein charmantes neues Restaurant, das als Geheimtipp für Fans der italienischen Küche gilt. Bei Partenope dreht sich alles um das Meer — authentische Fischküche wird auf den Teller gebracht, mit Fokus auf frische Zutaten und traditionelle Zubereitung. Mariahilf bekommt damit ein hochwertiges Seafood-Lokal, das sich wohltuend von den üblichen Pasta-und-Pizza-Konzepten abhebt.

Goodnight.at • März 2026
Neueröffnung

Der schöne Ernst — Kaffee & Aperitivo auf der Praterstraße

Eine neue Kaffee- und Aperitivo-Bar im Hotel Henriette auf der hippen Praterstraße, wo sich lokalmäßig einiges tut. Hier setzt man auf Sprizz-Varianten, Prosecco vom Fass und Brötchen. Ideal für den Vormittagskaffee oder den Feierabend-Aperitif.

Vienna Meeting • 2026
Neubau

L'Autentico — Neapolitanische Pizza in der Schottenfeldgasse

André und Sandro Gargiulo eröffneten L'Autentico in Wien-Neubau mit Fokus auf authentische neapolitanische Pizza und Aperitivo-Kultur. Das gemütliche Gründerzeithaus in der Schottenfeldgasse verspricht entspannte Stunden mit gutem Essen in stilvollem Ambiente.

WienNeu • Jänner 2026